Latigo Biotherapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LTGO research report →
Range $36 – $73
Price Chart
About the company
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418.
- CEO
- Todd N. Smith
- IPO
- 2026
- Employees
- 66
- HQ
- Thousand Oak, CA, US
Get TickerSpark's AI analysis on LTGO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $781.99M
- P/E
- -8.93
- PEG
- 0.10
- P/S
- 0.00
- P/B
- 1.29
- EV/EBITDA
- -3.76
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 117.14%
- ROIC
- -27.98%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-110,392,000
- Net Income
- $-109,167,000+0.0%
- EPS
- $-2.48+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $25.93
- 52W Low
- $10.24
- 50D MA
- $16.26
- 200D MA
- $17.96
- Beta
- 0.00
- RSI (14)
- 41
- Avg Volume
- 308.51K
No earnings-call transcripts are available for LTGO yet.
- Free Float
- 23.3%
- Shares Outstanding
- 66.30M
- Float Shares
- 15.45M
Buy/sell ratio 1.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 47 ETFs
Biggest fund positions in LTGO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 26 | Singla Neil | other | 350,000 |
| Nov 15, 26 | Krishnamohan Neha | other | 175,000 |
| Nov 15, 26 | SMITH TODD N | other | 2,207,516 |
| Aug 10, 26 | 5AM Ventures VI, L.P. | other | 4,975,543 |
| Aug 10, 26 | 5AM Ventures VI, L.P. | other | 2,350,419 |
| Aug 10, 26 | 5AM Ventures VI, L.P. | other | 3,152,305 |
| Aug 10, 26 | 5AM Ventures VI, L.P. | other | 866,018 |
| Aug 10, 26 | 5AM Ventures VI, L.P. | other | 1,484,401 |
| Aug 10, 26 | Sanofi | other | 177,978 |
| Aug 10, 26 | Sanofi | other | 494,800 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LTGO coverage
Recent articles, reports, and earnings notes.
Want a deeper read on LTGO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) Stock Has Consensus Price Target of $52.25 According to Analysts
defenseworld.net · Nov 7
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com · Nov 5
Latigo Biotherapeutics Announces CEO Transition to Support the Company's Next Phase of Growth
globenewswire.com · Nov 5
Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November
globenewswire.com · Nov 3
Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It
seekingalpha.com · Oct 11
Latigo Biotherapeutics (NASDAQ:LTGO) Hits New 12-Month Low – Here’s Why
defenseworld.net · Oct 8
Latigo Biotherapeutics, Inc.’s Quiet Period Will End on September 16th (NASDAQ:LTGO)
defenseworld.net · Sep 9
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com · Sep 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
